Astec LifeSciences Limited — Dividend/Bonus, 23-04-2025: Record Date

Astec LifeSciences Limited has approved its audited financial results for the quarter and financial year ended 31st March, 2025. The company reported a standalone loss of ₹1,609.85 lakh, while the consolidated loss amounted to ₹1,607.90 lakh. Revenue from operations for the period was ₹11,952.70 lakh, a significant decline from previous periods. The annual general meeting is set for 28th July, 2025, with book closure from 23rd to 27th July. The board also noted changes in management designations and proposed related party transactions for the upcoming financial year.